Biochem/physiol Actions

Cell permeable: no

Reversible: no

Product does not compete with ATP.

Primary TargetHMG-CoA reductase

General description

This is an inactive form which may require activation for use with isolated cells depending upon the application. To activate, treat with NaOH in ethanol and then neutralize to pH 7.2.

An antibiotic that acts as a potent inhibitor of HMG-CoA reductase, thus suppresses Ras farnesylation. Inhibitor of myoblast fusion. Causes cell cycle arrest in late G₁ phase. May induce bone morphogenic protein-2 (BMP-2). This product requires activation for use in cell culture and cell-free assay systems. To activate, treat with ethanol solution with 1 N NaOH and then neutralize with 1 N HCl to pH 7.2 (see Keyomarsi, K . et al. 1991).

An antibiotic that acts as a potent inhibitor of HMG-CoA reductase, thus suppressing Ras farnesylation. Inhibitor of myoblast fusion. Also may induce bone morphogenic protein-2 (BMP-2). Causes cell cycle arrest in late G₁ phase.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Sugiyama, M., et al. 2000. Biochem. Biophys. Res. Commun.271, 688.Hug, T., et al. 1995. Pflugers Archiv. Eur. J. Physiol.429, 682.Belo, R.S., et al. 1993. Mol.Cell. Biochem.126, 159.McLeish, K.R., et al. 1993. Biochem. Biophys. Res. Commun.197, 763.Keyomarsi, K., et al. 1991. Cancer Res. 51, 3602.Jackson, J.H., et al. 1990. Proc. Natl. Acad. Sci. USA 87, 3042.Kita, T., et al. 1980. J. Clin. Invest. 66, 1094.

Packaging

50 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.

Warning

Toxicity: Standard Handling (A)